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Abstract
Chagas’ disease is caused by the protozoan parasite Trypanosoma cruzi and affects approximately 10 million people in
endemic areas of Mexico and Central and South America. Currently available chemotherapies are limited to two
compounds: Nifurtimox and Benznidazole. Both drugs reduce the symptoms of the disease and mortality among infected
individuals when used during the acute phase, but their efficacy during the chronic phase (during which the majority of
cases are diagnosed) remains controversial. Moreover, these drugs have several side effects. The aim of this study was to
evaluate the effect of Memantine, an antagonist of the glutamate receptor in the CNS of mammals, on the life cycle of T.
cruzi. Memantine exhibited a trypanocidal effect, inhibiting the proliferation of epimastigotes (IC50 172.6 mM). Furthermore,
this compound interfered with metacyclogenesis (approximately 30% reduction) and affected the energy metabolism of the
parasite. In addition, Memantine triggered mechanisms that led to the apoptosis-like cell death of epimastigotes, with
extracellular exposure of phosphatidylserine, increased production of reactive oxygen species, decreased ATP levels,
increased intracellular Ca2+ and morphological changes. Moreover, Memantine interfered with the intracellular cycle of the
parasite, specifically the amastigote stage (IC50 31 mM). Interestingly, the stages of the parasite life cycle that require more
energy (epimastigote and amastigote) were more affected as were the processes of differentiation and cell invasion.
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Introduction
Trypanosoma cruzi is the etiological agent of Chagas’ disease,
which affects approximately 10 million people living in endemic
areas of Mexico and Central and South America, with 28 million
people at risk of infection [1]. T. cruzi has a complex life cycle that
alternates between a reduviid insect vector and mammalian hosts
(humans among them). During its biological cycle, the parasite
differentiates several times between infective, non-dividing forms
and dividing forms that inefficiently or are unable to infect
mammalian cells. Epimastigotes, the replicative form in the insect
vector, colonize the digestive tract and differentiate into metacyclic
trypomastigotes, the insect-derived infective form, in the terminal
midgut. During a blood meal on a mammalian host, the insects
defecate and deposit these forms with the feces, which are
internalized by the mammalian host and invade cells where they
differentiate into the replicative amastigote stage in the cytoplasm.
Amastigotes replicate by binary fission until differentiating into
mammal-derived trypomastigotes, passing through a transient
epimastigote-like stage [2,3]. These trypomastigotes induce the
lysis of the host cells, bursting into the extracellular milieu where
they invade new cells or reach the bloodstream. The parasites
disseminate throughout the infected mammal through the blood
and can eventually be taken up by a new reduviid insect during a
blood meal. In the midgut, the ingested trypomastigotes differen-
tiate into epimastigotes, which replicate, thereby colonizing a new
insect vector [3].
The clinical evolution of Chagas’ disease in humans can be
divided into two phases: acute and chronic. The acute phase is
usually asymptomatic with patent parasitemia and non-specific
symptoms. The chronic phase is characterized by infrequent tissue
parasitism and subpatent parasitemia that persists for the life of the
host. Most patients in the chronic phase (60–70%) will never
develop clinically apparent disease. However, approximately 30–
40% of chronic patients will develop important physiological
alterations: the heart is affected, with hypertrophy and dilatation,
and furthermore, the digestive tract, mainly the esophagus and
large intestine, are affected, with dilatation and the appearance of
megaviscera [4–6] as reviewed in reference [7].
Chemotherapy relies on two drugs that were discovered
approximately 40 years ago: Nifurtimox and Benznidazole. Both
drugs are effective for treating the acute phase of the disease.
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However, their efficacy in treating the chronic phase, when most
patients are diagnosed, is controversial [7]. Moreover, drawbacks
for both drugs have been reported, such as serious toxic side effects
and more recently, the emergence of drug-resistant parasites.
These facts underscore the urgent need to intensify the search for
new drugs against T. cruzi [7,8].
Our group has been exploring drug repositioning strategies,
which are being widely employed for the discovery of novel
therapeutic strategies to treat tropical diseases [9,10]. This
strategy seeks new uses for drugs that are already approved for
the treatment of diseases in humans. Paveto and colleagues have
suggested that T. cruzi epimastigotes have an N-methyl-D-
aspartate (NMDA)-type L-glutamate receptor that is involved in
the control of cytosolic Ca2+ levels, functionally analogous to that
reported in neural cells [11]. Moreover, our group characterized
a glutamate transporter [12] which is able to bind NMDA,
behaving as a glutamate receptor (unpublished data). In addition,
analogs of amantadine and Memantine (1,2,3,5,6,7-hexahydro-
1,5:3,7-dimethano-4-benzoxonin-3-yl)amines with NMDA recep-
tor antagonist activity were also demonstrated to have significant
trypanocidal activity against Trypanosoma brucei [13]. These data
led us to hypothesize that trypanocidal activities are present in
compounds directed against mammalian glutamate receptors. In
the present work, we tested the anti-T. cruzi activity of three
compounds that have antagonistic effects on NMDA receptors:
Amantadine and Memantine, tricyclic amines with low-to-
moderate affinity for the NMDA receptor and used for the
treatment of Alzheimer’s disease [14], and MK-801, which is
currently being tested in preclinical studies [15]. Memantine, an
uncompetitive blocker of continuously overactivated NMDA
receptors in neurons, exhibited the highest antiproliferative
activity on epimastigotes and a relevant trypanocidal effect
against infective forms of T. cruzi. Our experiments show that
Memantine mobilizes intracellular Ca2+ and induces apoptosis,
which supports the presence of a receptor with similar activity to
glutamate NMDA receptors that can be used as drug targets
against this parasite.
Materials and Methods
Reagents
Memantine was purchased from TOCRIS; MK-801, MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltretazolium bromide) and a
kit for bioluminescent somatic cells were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Amplex red, horseradish perox-
idase, Fluo-4 AM and annexin V-FITC were purchased from
Invitrogen (Eugene, Oregon, USA). Culture medium and fetal calf
serum (FCS) were purchased from Cultilab (Campinas, SP, Brazil).
Cells and parasites
The Chinese Hamster Ovary cell line (CHO-K1) was cultivated
in RPMI medium supplemented with 10% heat-inactivated FCS,
0.15% (w/v) NaCO3, 100 units mL
21 penicillin and 100 mg mL21
streptomycin at 37uC in a humidified atmosphere containing 5%
CO2. T. cruzi CL strain clone 14 epimastigotes [16] were
maintained in the exponential growth phase by subculturing
every 48 h in Liver Infusion Tryptose (LIT) medium supplement-
ed with 10% FCS at 28uC. Trypomastigotes were obtained by
infection of CHO-K1 cells with trypomastigotes as described
previously [17]. Trypomastigotes were collected from the extra-
cellular medium five or six days after infection.
Growth inhibition assays
T. cruzi epimastigotes in the exponential growth phase (5.0–
6.06107 cells mL21) were cultured in fresh LIT medium. The cells
were treated with different concentrations of drugs or not treated
(negative control). A combination of Rotenone (60 mM) and
Antimycin (0.5 mM) was used as a positive control for inhibition as
previously described [5]. The cells (2.56106 mL21) were trans-
ferred to 96-well culture plates and incubated at 28uC. Cell
proliferation was quantified by reading the optical density (OD) at
620 nm for eight days. The OD was converted to cell density
values (cells per mL) using a linear regression equation previously
obtained under the same conditions. The concentration of
compounds that inhibited 50% of parasite proliferation (IC50)
was determined during the exponential growth phase (five days) by
fitting the data to a typical sigmoidal dose-response curve using
OriginPro8. The compounds were evaluated in quadruplicate in
each experiment. Except where otherwise indicated, for experi-
mental purposes epimastigotes (1.06106 cells mL21) were cultured
in LIT and treated with a concentration corresponding to the IC50
(172.6 mM) Memantine or not treated (control). Before conducting
the experiments, epimastigotes were washed twice in PBS and
resuspended in 50 ml of binding buffer (10 mM HEPES, 140 mM
NaCl and 2.5 mM CaCl2, pH 7.4). The results shown here
correspond to three independent experiments.
Analysis of extracellular phosphatidylserine exposure
Parasites were treated with Memantine for four days or not
treated (control). Annexin V-FITC and propidium iodide were
added to the final concentration indicated by the manufacturer.
The cells were analyzed by flow cytometry on a Guava cytometer
(General Electric).
Hydrogen peroxide production
Epimastigote were treated with Memantine for 24 hours,
washed and resuspended in PBS (5 mM succinate). The cells
were incubated with 12 mM amplex red and 0.05 U mL21
horseradish peroxidase. Fluorescence was monitored at a lexcitation
of 563 nm and a lemission of 587 nm on a Spectra Max M3
fluorometer (Molecular Devices). Calibration was performed using
hydrogen peroxide as a standard.
Author Summary
Trypanosoma cruzi is a parasite transmitted to mammal
hosts by insect vectors known as kissing bugs. This species
can result pathogenic for humans, causing Chagas’ disease
in the Americas. Its treatment relies on two drugs
discovered more than 40 years ago. Besides their toxicity,
a main drawback of these drugs is the fact that they are
highly efficient only during the acute phase of the
infection. But due to the lack of specific symptoms, the
acute phase of the infection is largely not diagnosed. In
fact, most of patients are diagnosed in the chronic phase,
where the treatments are not satisfactory. In view of that, it
is urgent to look for new drugs with low toxicity and able
to kill the parasite in chronic patients. On the basis of
previous finding, we looked for drugs against glutamate
recognizing surface molecules, keeping special attention
on those that are already in use in humans for other
purposes (this strategy is called drug repositioning, and
allow to save time and money in clinical trials: several
parameters such as toxicity, pharmacokinetics, side effects
in humans are already known). Here we report that
Memantine, a NMDA glutamate receptors antagonist
already in use to treat Alzheimer’s disease, presents
interesting perspectives as a trypanocidal drug.
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Analysis of intracellular Ca2+ levels
Parasites (1.06108 cells) treated Memantine for four days were
incubated with 5 mM Fluo-4 AM (Invitrogen) for one hour at
28uC. After this period, the cells were washed twice with HEPES-
glucose (50 mM HEPES, 116 mM NaCl, 5.4 mM KCl, 0.8 mM
MgSO4, 5.5 mM glucose and 2 mM CaCl2, pH 7.4), resuspended
in the same buffer and distributed into 96-well plates (2.56107 per
well) in triplicate. Readings were performed on a Spectra Max M3
fluorometer using a lexcitation of 490 nm and a lemission of 518 nm
[18].
Determination of T. cruzi intracellular ATP levels
Intracellular ATP levels were measured in treated (or not)
epimastigote forms. To assess the effect of Memantine on the levels
of intracellular ATP, a kit for bioluminescent somatic cells
purchased from Sigma-Aldrich was used according to the
manufacturer’s instructions. Briefly, 50 ml of PBS was added to
100 ml of cellular ATP-releasing reagent and added to 50 ml of
parasite suspension containing 5.06106 treated or untreated
(control) cells mL21. The concentration of ATP was determined
using a standard curve of different concentrations of ATP.
Luminescence was obtained by the reaction between luciferase
and the ATP that was released after cell lysis. Light emission levels
were measured on a Lumat LB 9507 luminometer at 570 nm.
Effect of Memantine on metacyclogenesis
Epimastigotes (5.06106 cells mL21) were grown in LIT
medium, transferred to Grace’s medium [19] and treated or not
treated (control) with 172.6 mM Memantine (IC50 value). On the
sixth day, after transfer, the parasites were counted in a Neubauer
chamber, and the percentage of metacyclic forms was determined.
Effect of Memantine on mammalian cell viability
CHO-K1 cells (5.0610
5 cells mL21) were seeded in 24-well
plates in RPMI medium supplemented with FCS (10%) with
different concentrations of drugs or not treated (control). Cell
viability was evaluated 48 h after the initiation of treatment using
the MTT assay [20]. The IC50 was determined by fitting the data
to a typical sigmoidal dose-response curve using OriginPro8.
Effect of Memantine on trypomastigote invasion
CHO-K1 cells (5.0610
4 per well) were maintained in 24-well
plates in RPMI medium supplemented with 10% FBS and
maintained at 37uC. After 24 h, the cells were infected with
trypomastigote forms (2.56106 per well) and treated with different
concentrations of Memantine (50–300 mM) for four hours. After
this period, free parasites and the Memantine were removed. The
infected cells were washed twice with PBS. The RPMI medium
was replaced, and the plates were incubated at 33uC. Trypomas-
tigotes were collected from the extracellular medium on the fifth
day and counted in a Neubauer chamber.
Effect of Memantine on trypomastigote bursting
CHO-K1 cells (5.0610
4 per well) were maintained in 24-well
plates in RPMI medium supplemented with 10% FBS and
maintained at 37uC. After 24 h, the cells were infected with
trypomastigote forms (2.56106 per well) for four hours. After this
period, free parasites were removed. The infected cells were
washed twice with PBS, the RPMI medium was replaced, and the
cells were kept in culture in the presence of different concentra-
tions of Memantine (5–300 mM). The plates were then incubated
at 33uC. Trypomastigotes were collected from the extracellular
medium on the fifth day and counted in a Neubauer chamber.
Effect of Memantine on intracellular stages
CHO-K1 cells (5.0610
4 per well) were maintained in 24-well
plates in RPMI medium supplemented with 10% FBS and
incubated at 37uC. After 24 h, the cells were infected with
trypomastigote forms (2.56106 per well) for four hours. The
infected cells were washed twice with PBS, the RPMI medium was
replaced, and the cells were treated at different times during
invasion, after 24 h (amastigote stage) and after 60 h (epimasti-
gote-like stage) with 31 mMMemantine (corresponding to the IC50
value obtained for the treatment of infected cells). The plates were
incubated at 33uC. Trypomastigotes were collected from the
extracellular medium on the fifth day and counted in a Neubauer
chamber.
Statistical analysis
One-way ANOVA followed by the Tukey post-test was used for
statistical analysis. The T test was used to analyze differences
between groups. P,0.05 was considered statistically significant.
Results
Memantine affects the growth of epimastigote forms
To investigate the possible presence of targets for mammalian
NMDA glutamate receptor inhibitors, leading to a trypanocidal
activity, Amantadine, Memantine and MK-801 were evaluated. A
preliminary screening for the ability of these compounds to inhibit
epimastigote growth was performed. T. cruzi epimastigotes were
cultured in LIT medium with different concentrations of the
selected drugs or no drug (control). Amantadine, Memantine and
MK-801 produced a dose-dependent inhibition of epimastigote
growth at 28uC and pH 7.5, the optimal growth conditions for
these cells. The observed growth differences between the treated
cells and the control were statistically significant (p,0.05), and the
IC50 was determined to be 172.6 mM for Memantine, 300 mM for
MK-801 and 451.2 mM for Amantadine (Figure 1A, 1B and 1C,
respectively). In spite of being a relatively high IC50 when
compared to that obtained herein for Benznidazole, (which
resulted to be 7 mM, see Figure S1), the fact that Memantine is
considered a safe drug for humans (few side effects have been
reported) at relatively high doses (up to 20 mg/kg day), together
with the facts that is commercially available and is inexpensive, led
us to choice it for further study by investigating its effects on the
biological processes of T. cruzi.
Memantine leads to ROS production, transient increases
in intracellular Ca2+ and programmed cell death (PCD) in
epimastigote forms
Programmed cell death is characterized by morphological and
biochemical changes. A major change observed in cells undergo-
ing PCD is exposure of phosphatidylserine on the extracellular
face of the cytoplasmic membrane. Treated parasites were
incubated with annexin V-FITC to assess external exposure of
phosphatidylserine (feature of PCD) and propidium iodide to
assess the possible rupture of the parasite membrane (feature of
necrosis), and were further evaluated by flow cytometry. As shown
(Figure 2A), untreated parasites (control) showed 10% positivity for
phosphatidylserine exposure, whereas the parasites treated with
Memantine showed 42% positivity (Figure 2B). Another type of
necrotic process was excluded because the maintenance of parasite
membrane integrity was confirmed by the absence of propidium
iodide staining (Figure 2C). To confirm that Memantine induces
apoptosis in epimastigotes, hallmarks for this process in trypano-
somatids, such as an increase in reactive oxygen species (ROS),
Memantine Induces Apoptosis in Trypanosoma cruzi
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decreased ATP levels, increased intracellular Ca2+ levels and cell
shrinkage [21–23], were explored. To evaluate the production of
H2O2 in parasites treated with Memantine, epimastigote forms
were treated with 172.6 mM Memantine (concentration corre-
sponding to the IC50 value). After treatment for 24 hours, the
parasites were incubated with amplex red and horseradish
peroxidase. As observed, treated parasites produced a slightly
increased amount of H2O2 than untreated parasites (Figure 3A).
To determine intracellular concentrations of Ca2+, epimastigote
forms were incubated with Memantine (172.6 mM) or no drug
(control) for four days. After treatment, the parasites were
incubated with Fluo-4 and analyzed by fluorometry. Treated
Figure 1. Growth curve of epimastigote forms of Trypanosoma cruzi. Left: growth curves in the presence of different concentrations of
compounds. Treatments with (A) Memantine (MM), (B) MK-801, (C) Amantadine (AMT); at 28uC and 7.4 pH: black square: 0 mM; black up-pointing
triangle: 30 mM (MM or AMT), 100 mM (MK); black down-pointing triangle: 60 mM (MM), 90 mM (AMT), 200 mM (MK); black left-pointing triangle: 90 mM
(MM), 150 mM (AMT), 300 mM (MK); black right-pointing triangle: 120 mM (MM), 250 mM (AMT), 400 mM (MK); black diamond: 150 mM (MM), 400 mM
(AMT), 500 mM (MK); black pentagon: 180 mM (MM), 500 mM (AMT), 600 mM (MK); black hexagon: 210 mM (MM), 700 mM (AMT or MK); black star:
250 mM (MM), 1,000 mM (AMT), 800 mM (MK); inverse white circle: 300 mM (MM), 1 mM (MK); black circle: Inhibition control (0.5 mM antimycin and
60 mM rotenone). Right: dose-response curves.
doi:10.1371/journal.pntd.0002717.g001
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parasites exhibited higher intracellular Ca2+ concentrations
compared with untreated parasites (Figure 3B). The levels of
intracellular ATP in treated and untreated cells were also
determined using a bioluminescence assay. Intracellular ATP
levels decreased in the treated parasites compared with the control
(untreated parasites) (Figure 3C), indicating that the energy
metabolism of the parasite is affected by the drug. Finally, we
evaluated potential morphological changes in treated parasites
compared with the control (Figure 4). Epimastigotes treated with
Memantine exhibit dramatic changes in morphology (Figure 4C–
D), presenting a characteristic rounded shape corresponding to
shrinkage, a feature that is also described for apoptotic cells
including trypanosomatids [23,24]. These changes were reflected
by changes on the values obtained for the forward and side light
scattering (Table 1).
Effect of Memantine on metacyclogenesis
Because Memantine produced apoptotic activity in epimasti-
gotes, we evaluated whether the drug could interfere with parasite
differentiation. Metacyclogenesis is a well-characterized process in
T. cruzi that involves transient modulation of Ca2+ levels and is
dependent upon the parasite’s metabolic status [25], both of which
were affected by Memantine. On this basis, we evaluated the effect
of Memantine on metacyclogenesis. Memantine-treated parasites
sustained a 30% decrease in the number of metacyclic forms
compared with the control (parasites without treatment) (Figure 5).
Effect of Memantine on invasion and the intracellular
cycle of T. cruzi
To evaluate the effect of treatment on the intracellular forms of
the parasites, we first evaluated the toxicity of Memantine for
mammalian CHO-K1 cells by MTT assay to avoid cytotoxic doses.
Memantine was well tolerated by CHO-K1 cells, with an IC50 of
624.5646 mM (Figure 6A). Based on this result, we evaluated the
effect of Memantine on parasite infection using concentrations up to
0.4 mM (below the IC50 for CHO-K1 cells). To verify the effect of
the drug on trypomastigote infectivity, CHO-K1 cells were infected
and treated with different concentrations of Memantine (ranging
from 50 to 400 mM) or not treated (control). The parasites were
treated for four hours (the interval corresponding to the process of
cell invasion). At all concentrations, a significant decrease in the
number of trypomastigotes released from the lysed treated cells on
the 5th day after infection was observed compared with the control,
indicating that Memantine interferes with the infection process, and
the IC50 under these conditions was determined to be 206.3 mM
(Figure 6B). We also evaluated the effect of treatment after invasion
of the mammalian cells by T. cruzi. All treatments produced a
significant reduction in trypomastigote bursting on the 5th day after
infection compared with the control (Figure 6C). This result suggests
that Memantine also interferes with processes involved in the
intracellular cycle. Under these conditions, the IC50 value was
31 mM, less than 20 times the IC50 for CHO-K1 cells (selectivity
index: 20.13).
Given the effects of treatment of infected cells throughout the
entire infection cycle, we determined which stages of the
intracellular cycle (trypomastigote, amastigote or epimastigote-
like) are more susceptible to treatment with Memantine. To
explore this question, we took advantage of the fact that the CL14
strain produces a synchronic infection in CHO-K1 cells as
previously reported [17]. In this experiment, 31 mM Memantine
(concentration corresponding to the IC50 value when applied
throughout the infection) was added to the infected cultures at
different times: period of infection (four hours), between 24 and
60 hours post-infection (when the parasites are in the host-cells
cytoplasm, as amastigotes) and between 60 and 96 hours post-
infection (when most of the intracellular parasite population is at
the epimastigote-like stage and differentiating into trypomasti-
gotes). The stage most susceptible to treatment was the amastigote
stage (Figure 6D), with a 35% decrease in the number of egressed
trypomastigotes compared with the control.
Discussion
The discovery of novel drugs for neglected diseases is a necessity
for the development of more efficient chemotherapies. However,
some alternative strategies should be followed in parallel to
accelerate the process of optimizing the treatment of these
diseases. In this sense, the search for new therapeutic uses (in
this case, against T. cruzi) of well-known drugs already in use for
humans (such as Memantine) may help to reduce time- and
resource-consuming steps because parameters for their application
in humans (such as pharmacokinetics, toxicity, maximum tolerable
Figure 2. Analysis of extracellular phosphatidylserine exposure. Panel A: untreated parasites. Panel B: treated parasites. The parasites were
treated with Memantine (172.6 mM) or not treated (control) for 4 days. After this period, the parasites were labeled with propidium iodide (PI) and
annexin V and analyzed by flow cytometry. Panel C: quantitative analysis of three independent experiments (T test: ***: p,0.001).
doi:10.1371/journal.pntd.0002717.g002
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doses and interactions with other drugs) are already well
characterized [10,26]. Drug repositioning was the main objective
of the present work.
The uncompetitive NMDA receptor antagonists Amantadine,
Memantine, and MK-801, which are described in the pharma-
copeia as antagonists of NMDA glutamate receptors, exhibited
trypanocidal activity. These receptors have not been described in
T. cruzi at the molecular level, although evidence of their existence
in T. cruzi has been reported [11].
All three evaluated drugs produced a dose-dependent inhibition
of proliferation and death in T. cruzi epimastigotes. Interestingly,
Amantadine and Memantine, which share their basic structure
consisting in a tricyclic amine (Figure 7), were the less and the more
effective antagonists, respectively. The presence of two methyl
groups in Memantine, which are absent in Amantadine, diminished
the IC50 of the first with respect to the second by a factor of 2.5,
showing that little modifications on the leader structure can result in
an optimized drug. To investigate the mechanism of death, several
parameters were evaluated. First, the integrity of the cytoplasmic
membrane and the exposure of phosphatidylserine on the
extracellular face were evaluated and strongly suggested PCD with
the characteristics of apoptosis. This type of PCD has been
described for unicellular protists, including T. cruzi, Leishmania and
Plasmodium [27–30]. Similar to metazoans, apoptosis is triggered by
changes in mitochondrial function. The role of mitochondria in
different PCD processes including apoptosis is well characterized
[21–23]. The production of ROS together with diminished
intracellular ATP levels suggest this organelle as a main actor in
gating this process. Second, increased intracellular Ca2+ levels and
morphological changes were consistent with this cell death
mechanism. Taken together, these results demonstrate that
Memantine triggers PCD with characteristics of apoptosis.
Given that Memantine alters epimastigote physiology, we were
interested in determining whether in addition to PCD, this drug
may also interfere with differentiation into metacyclic trypomas-
tigotes (metacyclogenesis). This process normally occurs in the
terminal midgut of the insect vector. It is worth noting that
differentiation requires initial metabolic stress conditions and is
Figure 3. Quantification of H2O2, Ca
2+ and ATP levels in T. cruzi. Panel A: H2O2 levels, parasites treated with Memantine (172.6 mM) or not
treated (control) for 24 hours. After this period, the parasites (1.06107) were incubated with 25 mM amplex red, and 0.05 U mL21 horseradish
peroxidase and analyzed on a fluorometer (lex 563 nm and lem 587 nm). Panel B: Ca
2+ levels, parasites were treated for 4 days and incubated with
Fluo-4 AM (5 mM) for 1 hour at 28uC, washed twice in HEPES-glucose and evaluated on a fluorometer (lex 490 nm and lem 518 nm). Panel C: ATP
levels, parasites were treated for 30 hours, and the levels of ATP were assessed using a bioluminescent assay kit (Sigma-Aldrich) and analyzed on a
luminometer (l 570 nm). T test: *: p,0.05; **: p,0.01; ***: p,0.001.
doi:10.1371/journal.pntd.0002717.g003
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mainly energetically supported by amino acids present in reduviid
urine and feces, such as proline, aspartate and glutamate [31].
These amino acids allow the parasite to reestablish the intracel-
lular ATP levels required to energize metacyclogenesis [32].
Because Memantine reduces parasite ATP levels, we propose that
the inhibition of metacyclogenesis occurs as a result of low ATP
levels.
To evaluate Memantine as a trypanocidal of interest for
developing new treatments against T. cruzi infection, its effect
throughout the parasite life cycle in mammalian cells was
evaluated. Memantine affected the infectivity of trypomastigote
Figure 4. Trypanosoma cruzi epimastigote forms, 4th day of growth. Panel A and B: untreated parasites. Panel C and D, parasites treated with
Memantine (172.6 mM).
doi:10.1371/journal.pntd.0002717.g004
Table 1. Forward and side scattering values for
epimastigotes treated or not with Memantine.
Treatment 1Forward Scatter 1Side Scatter
Control 64.08 107.77
Memantine 110.58 68.79
1Geometrical mean of scatter values of epimastigotes treated or not with
172.6 mM Memantine.
doi:10.1371/journal.pntd.0002717.t001
Figure 5. Effect of Memantine on metacyclogenesis. Epimasti-
gote forms were grown in LIT medium, transferred to Grace’s medium,
and treated with Memantine (172.6 mM) or not treated. On the 9th day,
the number of metacyclic forms was determined in a Neubauer
chamber (T test: ***: p,0.001).
doi:10.1371/journal.pntd.0002717.g005
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Figure 6. Effect of Memantine on the intracellular cycle of Trypanosoma cruzi. Panel A: viability of CHO-K1 cells treated with different
concentrations of Memantine (range 50 mM to 1 mM). Viability was assessed by MTT assay. Panel B: effect on the infectivity of trypomastigotes
treated only during the period of infection (50–400 mM). Panel C: effect of treatment after invasion of parasites in CHO-K1 cells (5–300 mM). Panel D:
effect of Memantine on intracellular stages. Cells were treated at different stages with 31 mM Memantine (IC50 value): T (trypomastigote cell invasion),
A (amastigote) and IE (intracellular epimastigote-like) stages. In all experiments, we evaluated the burst of trypomastigotes on the fifth day post-
infection by counting parasites in a Neubauer chamber. Tukey test: *: p,0.05; **: p,0.01; ***: p,0.001.
doi:10.1371/journal.pntd.0002717.g006
Figure 7. Chemical structures of Memantine, Amantadine and MK-801.
doi:10.1371/journal.pntd.0002717.g007
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forms, which resulted in a reduced number of trypomastigotes
bursted from infected host cells. In addition, the amastigote stage
was shown to be the most sensitive stage among those infecting the
mammalian cells. This is particularly interesting because amasti-
gotes are the forms involved in maintenance of the chronic phase
of infection.
Taken together, these results reveal promising prospects for a
new use for Memantine, a drug that is already approved for use in
humans, as an anti-T. cruzi drug. Preclinical studies are underway
to support this proposal.
Supporting Information
Figure S1 A: Effect of Benznidazole (BZN) on epimastigotes of
T. cruzi proliferation. A: Growth curves of epimastigotes treated
with BZN at 28uC and 7.4 pH. black square: 0 mM; black up-
pointing triangle: 1 mM; black down-pointing triangle: 10 mM;
black left-pointing triangle: 20 mM; black right-pointing triangle:
30 mM; black diamond: 40 mM; black pentagon: 50 mM; black
hexagon: 60 mM; black star: 70 mM; black circle: 80 mM; inverse
white circle: Inhibition control (0.5 mM antimycin and 60 mM
rotenone). B: Dose - response curve for BZN.
(TIF)
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